Входя на эту страницу, Вы подтверждаете, что являетесь  медицинским работником.

Status message

Not the entire site translated, but only to "Journal"

Рolypharmacy with antipsychotics in the treatment of schizophrenia in clinical practice

M. V. Dorofeykov, N. N. Petrova
Department of psychiatry and narcology,
Federal state budgetary educational institution of higher professional education "Saint-Petersburg state University”

SUMMARY

Background. Despite the recommendations of the preferred use of antipsychotic monotherapy, use of antipsychotics in practice often differs from the developed algorithms. When a combination of antipsychotic drugs is used, prescribed doses often exceed recommended. Material and methods. We examined 38 patients with paranoid schizophrenia (47,4 %  female) undergoing treatment in three day hospital in St. Petersburg. “Brief assessment of cognitive functions in patients with schizophrenia” (BACS), “Complex figure of Rey-Osterrieth” as well as the Side Effect Rating Scale (UKU) and a self-report scale predictive of drug compliance (DAI) were used.

Results and discussion. It was found that nearly 60 % of outpatient receive more than one antipsychotic and 73,7 % are treated with first-generation antipsychotics. Polypharmacy was not the determining factor of the adherence to therapy and side effects. The average level of compliance reached 7,5 ± 1,5 points. It was found that more compliant patients have longer duration of disease (19,0 ± 9,0 vs. 10,8 ± 4,7 years, p = 0,008) and had undergone a greater number of hospitalizations (6,0 ± 3,7 vs. 3,0 ± 1,8, p = 0,017). They have better cognitive functioning (BACS total score 30,6 ± 13,7 vs. 18,8 ± 18,3 points, p = 0,071), particularly the level of planning and problem-solving behavior (48,2 ± 24,3 vs. 25,6 ± 47,8 points, p = 0,11) and speech fluency (38,4 ± 10,4 vs. 31,2 ± 10,5 points, p = 0,066). Treatment exclusively with second generation antipsychotics positively correlated with duration of disease of patients (r = 0,422; p = 0,008) and was associated with higher scores for speech fluency (r = 0,329; p = 0,047).

CONTACTS: petrova_nn@mail.ru

References: 
  • 1. Mosolov S.N., Tsukarzi E.E., Kapiletti S.G. Antipsikhoticheskaya farmakoterapiya shizofrenii: ot nauchnykh dannykh k klinicheskim rekomendatsiyam // Biologicheskie metody terapii psikhicheskikh rasstroistv / Pod red. S.N. Mosolova. Dokazatel'naya meditsina – klinicheskoi praktike. M., 2012. − S. 11−61.
  • 2. Gallego J.A., Bonetti J., Zhang J., Kane J.M., Correll C.U. Prevalence and Correlates of Antipsychotic Polypharmacy: A Systematic Review and Meta-regression of Global and Regional Trends from the 1970s to 2009 // Schizophrenia Research. – 2012. − Vol. 138 (1). – R. 18−28.
  • 3. Ganguly R., Kotzan J.A., Miller L.S. et al. Prevalence, trends, and factors associated with antipsychotic polypharmacy among Medicaid-eligible schizophrenia patients, 1998–2000 // J Clin Psychiatry. − 2004. − 65 (10). – R. 1377–1388.
  • 4. Elie D., Poirier M., Chianetta J., Durand M., Gregoire C., Grignon S. Cognitive effects of antipsychotic dosage and polypharmacy: a study with the BACS in patients with schizophrenia and schizoaffective disorder // J Psychopharmacol. – 2010. – Vol. 24. – R. 1037−1044.
  • 5. Lelliott P., Paton C., Harrington M. et al. The influence of patient variables on polypharmacy and combined high dose of antipsychotic drugs prescribed for inO patients // Psychiatric Bulletin. – 2002. – Vol. 26. – R. 411–414.
  • 6. Correll C.U., Frederickson A.M., Kane J.M. et al. Does antipsychotic polypharmacy increase the risk for metabolic syndrome? // Schizophr Res. – 2007. − Vol. 89 (1–3). – R. 91–100.
  • 7. Addington J., Addington D. Neurocognitive and social functioning in schizophrenia // Sch Bull. − 1999. − Vol. 25. − P. 173–182.
  • 8. Sarkisyan G.R., Gurovich I.Ya., Kif R.S. Normativnye dannye dlya rossiiskoi populyatsii i standartizatsiya shkaly «Kratkaya otsenka kognitivnykh funktsii u patsientov s shizofreniei» (BACS) // Sots. i klin. psikhiatriya. − 2010. − № 3. − S. 13−19.
  • 9. Vasserman L.I., Cherednikova T.V. Psikhologicheskaya diagnostika neirokognitivnogo defitsita: restandartizatsiya i aprobatsiya metodiki «Kompleksnaya figura Reya – Osterrita»: metodicheskie rekomendatsii. – SPb., 2011. – 68 s.
  • 10. Lindstrom E., Lewander T., Malm U., Malt U.F., Lublin H., Ahlfors U.G. Patient rated versus clinician rated side effects of drug treatment in schizophrenia. Clinical validation of a self-rating version of UKU Side Effect Rating Scale (UKU-SERS-Pat) // Nord J Psychiatry. 2001. − Vol. 44. − P. 5−69.
  • 11. Hogan T.P., Awad A.G., Eastwood R. A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity // Psychol Med. − 1983. − Vol. 13. − P. 177−183.
  • 12. Sair A., Bhui K., Hag S. et al. Improving treatment adherence among patients with chronic psychoses //. Psychiatric Bulletin. – 1998. – Vol. 22. – R. 77−81.
  • 13. Honer W.G., Procyshyn R.M., Chen E.Y.H., MacEwan G.W., Barr A.M. A translational research approach to poor treatment response in patients with schizophrenia: clozapine-antipsychotic polypharmacy // Journal of Psychiatry & Neuroscience: JPN. – 2009. – Vol. 34 (6). – R. 433–442.
  • 14. Taylor D.M., Smith L. Augmentation of clozapine with a second antipsychotic – a meta-analysis of randomized, placebo-controlled studies // Acta Psychiatr Scand. – 2009. – Vol. 119. – R. 419–425.
  • 15. Correll C.U., Rummel-Kluge C., Corves C. et al. Antipsychotic combinations vs monotherapy in schizophrenia: a meta-analysis of randomized controlled trials // Schizophr Bull. – 2009. − Vol. 35 (2).
  • – R. 443–457.
  • 16. Zink M., Englisch S., Meyer-Lindenberg A. Polypharmacy in schizophrenia // Curr Opin Psychiatry. – 2010.